EAM
MGNX icon

Exome Asset Management’s MacroGenics MGNX Stock Holding History

Exome Asset Management’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-125,900
Closed -$1.21M – 65
2023
Q4 		$1.21M Buy
+125,900
New +$870K 1.2% 33

Other funds holding MGNX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Exome Asset Management's MGNX Position: Q1 2024 in Review

Exome Asset Management sold out of MacroGenics (MGNX) in Q1 2024, closing a stake of 125,900 shares — an estimated $1.21M sold.

Exome Asset Management first reported a position in MGNX in Q4 2023 and held it in 1 quarter. The position peaked at $1.21M in Q4 2023. 163 funds tracked by Wall St. Rank hold MGNX as of Q1 2024.

  • Exome Asset Management reported no remaining MacroGenics position as of Q1 2024 after selling out during the quarter.
  • Exome Asset Management sold 125,900 MacroGenics shares in Q1 2024, an estimated $1.21M.
  • Exome Asset Management first reported a position in MacroGenics in Q4 2023 and held it in 1 quarter.
  • Exome Asset Management's MacroGenics position peaked at $1.21M in Q4 2023.
  • 163 funds tracked by Wall St. Rank held MacroGenics as of Q1 2024.

Based on Exome Asset Management's 13F filing for Q1 2024, filed 15 May 2024.